BlogTalkRadio uses cookies. By using our services, you're agreeing to our Cookies Policy. Got it

Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Evolution of Regulatory Policy For Cell/Gene Therapy

  • Broadcast in Science
Pharma Talk Radio

Pharma Talk Radio

×  

Follow This Show

If you liked this show, you should follow Pharma Talk Radio.
h:548881
s:11840580
archived

In this podcast, first recorded at the 2021 IO360° Summit, Dr Peter Marks, Center for Biologics Evaluation and Research (CBER), FDA, moderated a panel on the evolution of regulatory policy for cell/gene therapy.

Discussion points include:

  • What are the greatest challenges to the expeditious development of cell and gene therapies at this time?
  • How does the existing regulatory framework mesh with the current state of development of cell and gene therapy products?
  • What adaptations or adjustments to the regulatory framework that might further advance manufacturing or clinical development of these products?
  • Are there scientific developments coming that will require further adaptation or adjustment to the regulatory framework?

Panelists include:
Jeff Allen, PhD, Friends of Cancer Research
Anne Chew, PhD, University of Pennsylvania
Alberto Santagostino, Lonza Pharma & Biotech

To learn more about the upcoming 2021 IO360° conference, please visit www.io360summit.com

Comments